Heavy Menstrual Bleeding Treatment With a Levonorgestrel 52-mg Intrauterine Device.

ABSTRACT:

Objective

To evaluate heavy menstrual bleeding treatment outcomes with levonorgestrel 52-mg intrauterine device (IUD) use in participants without body mass index (BMI) or parity restrictions.

Methods

Investigators included participants aged 18-50 years with no pelvic or systemic pathology causing heavy menstrual bleeding at 29 U.S. centers in a prospective trial. Participants had up to three screening cycles with menstrual product collection for alkaline hematin blood-loss measurements. Investigators enrolled those with two menses with blood loss of 80 mL or more (values averaged for baseline blood loss), placed the IUD, and followed participants for up to six 28-day cycles. Participants collected any menstrual products used during cycles 3 and 6 for blood-loss measurement.

SUBMITTER: Creinin MD 

PROVIDER: S-EPMC10108838 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature